David D. Chang's most recent trade in AXT Inc was a trade of 754 Common Stock done . Disclosure was reported to the exchange on June 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 754 | 73,498 (0%) | 0% | - | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.47 per share. | 16 Mar 2026 | 47,763 | 5,150,599 (4%) | 0% | 2.5 | 117,975 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 46.00 per share. | 10 Mar 2026 | 20,000 | 72,744 (0%) | 0% | 46.0 | 919,918 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 38.42 per share. | 04 Mar 2026 | 20,000 | 92,744 (0%) | 0% | 38.4 | 768,476 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 38.53 per share. | 04 Mar 2026 | 20,000 | 112,744 (0%) | 0% | 38.5 | 770,638 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 1,387,931 | 1,387,931 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 392,586 | 392,586 | - | - | Restricted Stock Unit | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 02 Feb 2026 | 95,269 | 5,185,862 (4%) | 0% | 1.8 | 171,484 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.26 per share. | 21 Jan 2026 | 8,800 | 8,800 (0%) | 0% | 2.3 | 19,888 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 14.84 per share. | 09 Dec 2025 | 25,000 | 132,744 (0%) | 0% | 14.8 | 371,025 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 12.33 per share. | 28 Nov 2025 | 25,000 | 157,744 (0%) | 0% | 12.3 | 308,250 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 28 Nov 2025 | 25,000 | 182,744 (0%) | 0% | 10.7 | 268,000 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 05 Nov 2025 | 100,000 | 207,744 (0%) | 0% | 8.9 | 894,040 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 185,709 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 185,709 | 185,709 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 135,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 130,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 113,500 | 113,500 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 113,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 48,836 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 48,836 | 48,836 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 38,238 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 38,238 | 38,238 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 55,172 | 307,744 (0%) | 0% | - | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 14 Mar 2025 | 46,668 | 5,276,569 (4%) | 0% | 2.0 | 91,469 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 03 Feb 2025 | 46,003 | 5,317,237 (4%) | 0% | 1.7 | 77,285 | Common Stock |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 1,952,130 | 1,952,130 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 552,174 | 5,363,240 (4%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.90 per share. | 16 May 2024 | 344,828 | 4,810,106 (3%) | 0% | 2.9 | 1,000,001 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 23,323 | 252,572 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.33 per share. | 14 Mar 2024 | 53,393 | 4,465,278 (3%) | 0% | 4.3 | 231,192 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Chang D. David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 1,123,535 | 1,123,535 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | D. David Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 317,800 | 4,513,203 (3%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,924,464 | 4,193,911 (3%) | 1% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,492,200 | 1,492,200 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.56 per share. | 14 Mar 2023 | 22,340 | 2,269,447 (1%) | 0% | 5.6 | 124,210 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 15,238 | 205,926 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 2,195,512 | 2,195,512 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.65 per share. | 15 Mar 2022 | 23,648 | 2,289,652 (1%) | 0% | 7.6 | 180,879 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) |